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Abstract
Intervertebral disc (IVD) disease, which is characterised by 
age-related changes in the adult disc, is the most common 
cause of disc failure and low back pain. The purpose of 
this study was to analyse the potential of the biologically 
active polyphenol epigallocatechin 3-gallate (EGCG) 
for the treatment of painful IVD disease by identifying 
and explaining its anti-inflammatory and anti-catabolic 
activity. Human IVD cells were isolated from patients 
undergoing surgery due to degenerative disc disease 
(n = 34) and cultured in 2D or 3D. An inflammatory 
response was activated by IL-1β, EGCG was added, and 
the expression/activity of inflammatory mediators and 
pathways was measured by qRT-PCR, western blotting, 
ELISA, immunofluorescence and transcription factor 
assay. The small molecule inhibitor SB203580 was used 
to investigate the involvement of the p38 pathway in 
the observed effects. The analgesic properties of EGCG 
were analysed by the von Frey filament test in Sprague-
Dawley rats (n = 60). EGCG significantly inhibited the 
expression of pro-inflammatory mediators and matrix 
metalloproteinases in vitro, as well as radiculopathic pain in 
vivo, most probably by modulation of the activity of IRAK-
1 and its downstream effectors p38, JNK and NF-κB.
Keywords: Epigallocatechin 3-gallate, intervertebral 
disc degeneration, low back pain, IRAK-1, p38, NF-κB, 
inflammation, radiculopathy, EGCG.
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Introduction
Intervertebral disc (IVD) degeneration is a normal part 
of the aging process that starts in the late second or 
early third decade (Dagenais et al., 2008). Although 
often asymptomatic, specific histological, biochemical 
and functional changes have been observed during IVD 
degeneration. These changes are consistent with pain 
generation and disc degeneration has been suggested as the 
most common cause of low back pain in adults (Dagenais 
et al., 2008). Costs associated with health services for 
spinal problems have been estimated at 85.9 billion USD 
in 2005 in the United States (Dagenais and Haldeman, 
2012; Martin et al., 2008) and many studies have shown 
that indirect costs related to reduced productivity and 
subsequent impact on national economy are also significant 
(Dagenais et al., 2008).
 Degeneration of the IVD occurs due to an imbalance 
between anabolic and catabolic processes, leading to 
a loss in collagen and proteoglycan and a concomitant 
reduction in water content by enhanced exposure to 
matrix metalloproteinases (MMPs) and a disintegrin 
and metalloproteinase with thrombospondin motifs 
(ADAMTS) (Bibby et al., 2005; Le Maitre et al., 2007a; 
Pockert et al., 2009; Roberts et al., 2006; Vo et al., 
2013). These degenerative processes lead to mechanical 
dysfunction and altered stress distribution in the tissue, 
hence increasing the risk for load-induced structural 
failure in the annulus fibrosus (AF), so-called clefts, tears 
or fissures. Under these circumstances, pain sensation can 
be provoked by leakage of nucleus pulopsus (NP) material 
through the AF (i.e. disc herniation) and consequent 
irritation of spinal nerves (radiculopathy) and/or nerve 
infiltration into the compromised disc (nociception).
 However, even without a disc prolapse, the degenerated 
IVD can be painful, especially if high levels of pro-
inflammatory mediators are secreted. Cytokines, e.g. 
from the interleukin-1 (IL-1) superfamily, not only irritate 
nerve endings in the AF (Richardson et al., 2007), but also 
stimulate the production of matrix-degrading enzymes, 
hence further worsening the degenerative processes (Le 
Maitre et al., 2005; Shamji et al., 2010; Wuertz et al., 
2012). The healthy IVD is excluded from the development 
of immunologic tolerance as an immune-privileged organ 
with no access to systemic circulation (Sun et al., 2013). 
In contrast, diseased human discs are heavily invaded 
by blood vessels and nociceptive nerve fibres (Brisby, 
2006), so that anti-angiogenic and anti-neurogenic factors 
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are of therapeutic interest in terms of nociceptive pain 
(Sun et al., 2013). Once NP extrudes from the IVD to the 
systemic circulation, the immune system recognises it as a 
foreign body, leading to autoimmune reactions conducted 
by activated B and cytotoxic T lymphocytes, which may 
further enhance the destruction of NP tissue inside the 
disc (Geiss et al., 2007). On the other hand, some immune 
cells (macrophages, mast cells) might be beneficial to 
the regrowth of the IVD wounds and immune privilege 
maintenance at early stage of the degeneration (Peng et al., 
2006) as well as in the absorption of herniated NP (Doita 
et al., 2001; Gronblad et al., 1994; Sun et al., 2013). When 
conservative treatment (physical therapy, pharmacological 
treatment) fails, patients with disc herniation or painful 
degenerative disc disease are likely to undergo surgical 
interventions; discectomy in case of herniation, spinal 
fusion or disc replacement in case of disc disease. Imaging 
techniques such as MRI are a valuable tool to identify 
the source of pain in disc herniation patients, however in 
patients with degenerative disc disease, identification of the 
painful disc is error-prone and removal of the degenerated 
tissue has a negative impact on disc height or load-bearing 
capacity (Kandel et al., 2008). In the case of spinal fusion, 
a consequent risk for adjacent segment degeneration, with 
the need of additional surgeries, is also significant (Disch 
et al., 2008; Kandel et al., 2008; Richardson et al., 2007).
 Therefore, currently used procedures for the treatment 
of degenerative disc disease are not optimal. New, less 
invasive but more targeted strategies are being developed 
(Richardson et al., 2007). NP replacement, e.g. by the 
injection of biocompatible hydrogels with or without cells 
may have the potential to restore normal disc height and 
load distribution, as well as limit degenerative changes in 
adjacent discs (Richardson et al., 2007). Recently, tissue-
engineered IVDs that formed a functional motion segment 
were used to replace the degenerated discs in rodent caudal 
spine (Bowles et al., 2011) and chemical crosslinking was 
applied to stabilise the AF tissue in vitro (Hedman et al., 
2006). Anti-inflammatory and anti-catabolic substances 
that target the metabolism and inflammatory signalling 
within the IVD also represent a new, interesting treatment 
option (Klawitter et al., 2012a; Klawitter et al., 2012b; 
Sinclair et al., 2011; Wuertz et al., 2011).
 Epigallocatechin 3-gallate (EGCG) is a biologically 
active polyphenolic catechin present in green tea. 
EGCG forms 40-60 % of all green tea catechins and is 
reported to be responsible for the major health benefits 
of green tea due to its anti-oxidant, anti-aging and anti-
inflammatory properties, which are exhibited by direct or 
indirect interaction with many molecules and signalling 
transduction pathways in cells (Bode and Dong, 2009; 
Singh et al., 2011). EGCG was shown to have beneficial 
effects for a number of clinical conditions, including 
cancer, obesity, atherosclerosis, diabetes, liver and 
neurodegenerative diseases (Aggarwal and Shishodia, 
2006; Smid et al., 2012; Suzuki et al., 2012), with cell-type 
specific effects and modes of action (Singh et al., 2011; 
Suzuki et al., 2012). Although EGCG has chemopreventive 
and anticancer effects and acts synergistically with several 
anticancer drugs (Khan and Mukhtar, 2007), it has also 
been shown that EGCG can block the function of boronic 
acid proteasome inhibitors (Golden et al., 2009) and reduce 
the bioavailability of the novel oral multi-target tyrosine 
kinase inhibitor sunitinib (Ge et al., 2011). Moreover, the 
consumption of EGCG by pregnant women could increase 
the risk of innate acute myeloid leukaemia in children, 
because EGCG inhibits topoisomerase II activity not 
only in cancer cells, but also in the foetus. This can lead 
to the translocation at chromosome 11q23 involving the 
mixed-lineage leukaemia (MLL) gene (Lambert et al., 
2007; Strick et al., 2000). Therefore, EGCG is possibly 
contraindicated in particular cases.
 Beneficial effects of EGCG and green tea extract were 
described in osteoarthritic (OA) chondrocytes (Shen et al., 
2012), which bear similarities to IVD cells. It has recently 
been demonstrated that EGCG inhibits the general IL-1β-
induced response, but does not have significant anabolic 
effects in chondrocytes. The anti-inflammatory effect of 
EGCG in human chondrocytes is mainly mediated by 
inhibition of c-Jun N-terminal protein kinase (JNK) and 
nuclear factor kappa-light-chain-enhancer of activated 
B cells (NF-κB) activity (Ahmed et al., 2004; Akhtar 
and Haqqi, 2011). EGCG was shown to inhibit NF-κB 
activation by suppressing the degradation of its inhibitory 
protein in the cytoplasm (Rasheed et al., 2009). EGCG 
also reduces the activity of activator protein 1 (AP-1) 
transcription factor (Ahmed et al., 2004), p38 mitogen-
activated protein kinase (MAPK) (Rasheed et al., 2009) 
and blocks interleukin-1 receptor-associated kinase 1 
(IRAK-1) degradation (Akhtar and Haqqi, 2011) in OA 
chondrocytes. EGCG is able to inhibit the expression of 
cyclooxygenase 2 (COX-2) and prostaglandin E synthase 
(PGES) (Ahmed et al., 2002), which are both involved in 
the development and transduction of inflammation and 
pain. EGCG also potently blocks the toll-like receptor 4 
(TLR4) signalling pathway, which may play an important 
role in the occurrence and development of neuropathic 
pain in rats (Kuang et al., 2012). Based on the promising 
findings of EGCG effects in cartilage, we hypothesise 
that EGCG may also possess anti-inflammatory and anti-
catabolic effects in the IVD and thus have a potential for 
the treatment of pain and inflammation in degenerative 
disc disease.
Materials and Methods
Human IVD cell culture preparation
The study was approved by ethic committees 
Kantonale Ethikkommission Zürich EK-16/2005 and 
Ethikkommission des Kantons Luzern 1007IVD. Human 
NP tissue was removed from patients undergoing spinal 
surgery for degenerative disc disease or disc herniation 
after informed consent was granted. The details about 
the donors used in this study are listed in Table 1. Tissue 
was enzymatically digested using a mixture of 0.2 % 
collagenase NB4 (17454, Serva, Heidelberg, Germany) and 
0.3 % dispase II (04942078001, Roche, Basel, Switzerland) 
for 4-8 h at 37 °C and isolated primary cells were seeded 
in Dulbecco’s Modified Eagle’s Medium (DMEM/F12, 
D8437, Sigma, St. Louis, MO, USA) supplemented with 
10 % foetal calf serum (FCS, F7524, Sigma), penicillin 
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(50 units/mL), streptomycin (50 μg/mL) and ampicillin 
(125 ng/mL, 15240-062, Gibco, Carlsbad, CA USA) and 
sub-cultured up to passage 3 using 1.5 % trypsin (15090-
046, Gibco). Cells in passage 1-3 that were cultured either 
adherently (2D) or in alginate beads (3D) were used for 
experiments.
Alginate beads preparation
Alginate was prepared as a solution of 1.2 % alginic acid 
sodium salt (180947, Sigma-Aldrich, St. Louis, MO, USA) 
in 0.9 % sodium chloride, stirred overnight and sterile 
filtered. Human IVD cells in passage 1-3 were harvested 
with trypsin and gently mixed with alginate (4 x 106 cells 
per 1 mL of alginate). Alginate-cell suspension was slowly 
pushed through a sterile syringe with a 21G needle and 
dropped into a 102 mM calcium chloride solution with 
constant speed. Beads were formed after 5 min of stirring 
in the calcium chloride solution and then washed with 
0.9 % NaCl and phosphate-buffered saline (PBS). Beads 
were spread into 6-well plates with cell culture medium 
containing 50 µg/mL vitamin C (A4403, Sigma) and 
cultured for 7 d with one medium exchange.
Viability measurement
Non-toxic concentrations of EGCG (E4243, Sigma) were 
defined using the MTT assay in 2D cell culture. Cells were 
Table 1. Demographic data of all donors used for the experiments. STEN, discogenic 
stenosis; DH, disc herniation; DDD, degenerative disc disease; SP, spondylolisthesis; 
E, ELISA; G, gene expression; W, western blotting; V, viability; TF, transcription 
factor assay; IC, immunocytochemistry; uk, unknown.
Donor Sex Age Level Pathology Grade Experiment
1 F 43 L4/5 DH IV E(3D), G(3D), W
2 F 62 L4/5 SP V E(3D), G(3D), W
3 F 49 L5/S1 protrusion IV E(3D), G(3D)
4 M 42 C6/7 DH III E(3D), G(3D)
5 M 47 L2/3 DH IV E(3D), G(3D)
6 F 67 L4/5 DH IV E(3D), G(3D)
7 uk uk uk uk uk E(2D,3D), G(2D,3D)
8 M 50 L5/S1 SP III E(3D), G(3D)
9 uk uk uk uk uk E(3D), G(3D)
10 M 41 L4/5 DH IV E(2D), G(2D), G(SB), W
11 M 52 L1/2 DH V E(2D), G(2D), TF
12 F 53 C6/7 DH IV E(2D), G(2D), IS
13 F 46 L5/S1 DH V E(2D), G(2D), IS
14 M 42 L4/5 DH IV G(2D),W
15 M 39 L4/5 DH IV G(2D,3D), G(SB)
16 F 54 L3/4 SP V G(2D), TF
17 F 38 L5/S1 DH IV G(2D), G(SB), TF
18 M 59 L4/5 DH IV G(3D)
19 uk uk uk uk uk G(3D), W
20 M 59 L3/4 DH V G(2D), W 
21 M 57 L5/S1 DH V G(2D), W 
22 uk uk uk uk uk G(2D), G(SB)
23 M 48 L5/S1 DH IV G(2D), G(SB), W
24 uk uk uk uk uk G(3D), W
25 M 54 L4/5 DH III G(2D),W 
26 F 49 C4/5 DH II V, G(2D)
27 M 62 C5/6-C6/7 STEN III V, G(2D)
28 uk uk uk uk uk V, G(2D)
29 uk uk uk uk uk V, G(2D)
30 F 57 L3/4 SP III V, G(2D)
31 M 56 L5/S1 DH III V, G(2D)
32 M 63 L2/3 DH IV V, G(2D)
33 uk uk uk uk uk V, G(2D)
34 F 25 L5/S1 DDD III G(2D)
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seeded in 12-well plates (1 x 105 cells/well) and treated 
with different concentrations of EGCG (0.1-50 μM) in 
medium with 10 % FCS or without FCS. After 24 and 48 h, 
fresh MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide, M5655, Sigma) solution in PBS 
(0.5 mg/mL) was added and kept for 4 h in 37 °C. MTT was 
discarded, cells were lysed in DMSO (D8418, Sigma) and 
absorbance was measured at 565 nm relative to untreated 
controls. The non-toxic concentration of 10 μM was chosen 
for subsequent experiments.
Gene expression analysis (qRT-PCR)
The effect of EGCG on the expression of inflammatory 
mediators and matrix degrading enzymes was studied 
in 2D and 3D cell culture models that were pre-treated 
with IL-1β (211-11, Peprotech, Hamburg, Germany) in 
order to induce the expression of pro-inflammatory and 
catabolic genes and hence simulate the changes seen during 
inflammation-related disc degeneration (Le Maitre et al., 
2005; Mengshol et al., 2000). IVD cells were seeded in 
6-well plates (3 x 105 cells/well) (2D) or alginate beads 
(3D), serum-starved for 2 h and then exposed to 10 ng/
mL IL-1β for 2 h before treatment with 10 μM EGCG. 
The involvement of the p38 pathway was studied using 
the small molecule inhibitor of p38 MAPK SB203580 
(SB, S8307, Sigma), which was added 2 h after IL-1β 
pre-stimulation in the concentration of 10 µM to the cells 
seeded in 2D (n = 3 for MMPs and 4 for iNOS and COX-2). 
After 18 h, RNA was extracted with the Trizol/chloroform 
method according to the manufacturer instructions (15596-
018, Invitrogen, Carlsbad, CA, USA) and 1 µg was reverse 
transcribed to cDNA using a reverse transcription kit 
(4374966, Applied Biosystems, Foster City, CA, USA). 
cDNA was then mixed with primers and master mix 
(4352042, Applied Biosystems) and gene expression was 
measured using real-time PCR. Data was analysed by the 
comparative Cq method (2ΔΔCq method, housekeeping gene 
TATA box binding protein, TBP). Primer details are given 
in Table 2. Results are presented as gene expression relative 
to IL-1β pre-stimulation (100 %).
Western blotting
IVD cells seeded in 12-well plates (1 x 105 cells/well) were 
serum starved for 2 h and then exposed to 10 ng/mL IL-
1β for 2 h before treatment with 10 μM EGCG or 10 μM 
SB, 15 min for p-p38 (n = 9), p-JNK (n = 3) and IRAK-1 
(n = 5), 6 h for COX-2 (n = 1). For total protein analysis, 
cells were lysed in 0.1 % sodium dodecyl sulphate (SDS) 
buffer, mixed with Laemmli buffer (S3401, Sigma), heated 
(99 °C, 5 min) and lysates were loaded onto 10 % SDS-
polyacrylamide gels. Separated proteins were transferred to 
polyvinylidene difluoride (PVDF) membranes (RPN303F, 
GE Healthcare, Little Chalfont, UK) and membranes 
were blocked in 5 % non-fat milk in Tris-buffered saline-
Tween (TBS-T) for 1 h at room temperature. Primary 
antibodies were applied overnight at 4 °C. After washing 
in 1 % non-fat milk in TBS-T (3 × 10 min), membranes 
were incubated with secondary antibody conjugated to 
horseradish peroxidase (HRP) for 1 h at room temperature. 
Visualisation was performed on medical X-ray film 
(28906836, GE Healthcare) using a chemiluminescence 
kit West Dura (34076, Thermo Scientific, Waltham, MA, 
USA), films were scanned and scans were processed by 
GIMP2. Tubulin was used as a loading control. Antibodies 
and dilutions used: p38 MAPK, 1:1000 (9212, Cell 
Signaling, Danvers, MA, USA); phospho-SAPK/JNK, 
1:1000 (9251, Cell Signaling); phospho-p38MAPK, 
1:1000 (9211, Cell Signaling); α-Tubulin, 1:1000 (2144, 
Cell Signaling); IRAK-1, 1:1000 (4359, Cell Signaling); 
COX-2, 1:1000 (4842, Cell Signaling) and mouse anti-
rabbit IgG HRP, 1:5000 (211-032-171, Jackson Immuno 
Research, West Grove, PA, USA).
Immunocytochemistry
IVD cells (n = 2) seeded onto cover slips in Petri dishes 
were serum-starved for 2 h and then exposed to 10 ng/mL 
IL-1β alone or in combination with 10 μM EGCG. After 
1 h of simultaneous treatment, cells were washed with 
PBS (3 × 5 min), fixed with ice-cold methanol (10 min 
on ice), washed with PBS (3 × 5 min), and blocked with 
2 % BSA (A4503, Sigma) with the addition of 5 % goat 
serum (G9023, Sigma) (1 h at room temperature). Primary 
antibody p65 (RelA, the large subunit of NF-κB, Santa 
Cruz, sc-372, 1:200) was applied overnight at 4 °C. The 
next day, cells were washed with PBS (3 × 5 min) and 
secondary antibody (CY2 goat anti-rabbit IgG, Jackson 
Immuno Research, 111-165-144, 1:400) was applied for 
1 h at room temperature. After washing in PBS (3 × 5 min), 
DAPI (4’,6-diamidino-2-phenylindole, D9542, Sigma) 
was applied (5 min), cells were washed and embedded in 
Mowiol 4-88 (81381, Sigma). Analysis of p65 translocation 
was performed with a fluorescent microscope (Olympus 
IX51) and micrographs were processed in ImageJ. Cells 
without primary antibody were used as a non-specific 
Table 2. Primers used for real-time RT-PCR (TaqMan Gene Expression Assays, 
Applied Biosystems).
Gene Primer Sequence Number Base Pairs
TATA box binding protein (TBP) Hs00427620_m1 91
Interleukin-6 (IL-6) Hs00174131_m1 95
Interleukin-8 (IL-8) Hs00174103_m1 101
Matrix metalloproteinase-1 (MMP1) Hs00233958_m1 133
Matrix metalloproteinase-3 (MMP3) Hs00968308_m1 98
Matrixmetalloproteinase-13 (MMP13) Hs00233992_m1 91
Toll-like receptor 2 (TLR2) Hs00152932_m1 80
Cyclooxygenase-2 (COX-2) Hs00153133_m1 75
Inducible nitric oxide synthase (iNOS) Hs01075521_m1 82
Nerve growth factor (NGF) Hs00171458_m1 102
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binding control, untreated cells were used as a negative 
control, and cells treated with 10 ng/mL IL-1β were used 
as a positive control for p65 translocation. Antibodies and 
dilutions used: NF-κB p65,1:200 (sc-372, Santa Cruz, 
Dallas, TX, USA) and CY2 goat anti-rabbit IgG, 1:400 
(111-165-144, Jackson Immuno Research).
Nuclear extraction and transcription factor assay
Nuclear extracts were prepared using a Nuclear Extraction 
kit (10009277, Cayman, Ann Arbor, MI, USA). Cells 
(n = 3) were seeded in T75 flasks in the density 5 x 106 
cells/flask and pre-cultured 24 h. Cells were serum-starved 
for 2 h and then exposed to 10 ng/mL IL-1β alone or in 
combination with 10 μM EGCG. After 1 h of simultaneous 
treatment, nuclear extraction was performed according to 
the producer’s protocol. Briefly, cells were collected into 
15 mL pre-chilled tubes, centrifuged 2 times with kit PBS/
phosphatase inhibitor solution, and then re-suspended in 
ice-cold kit hypotonic buffer. After 15 min of incubation, 
10 % Nonidet P-40 was added, cells were centrifuged 
for 1 min at 140 x g, and supernatants containing the 
cytoplasmic fraction were collected. Pellets were further 
re-suspended in kit complete nuclear extraction buffer by 
vortexing (15 s), shaking (15 min on ice) and vortexing 
(15 s). Supernatants containing the nuclear fraction were 
collected into new pre-chilled tubes after 10 min of 
centrifugation (16000 x g, 4 °C). Protein concentration 
was determined using a BCA assay kit (23227, Thermo 
Scientific). NF-κB (p65) Transcription Factor Assay Kit 
(10007889, Cayman) was used for the assessment of 
NF-κB (p65) DNA-binding activity in nuclear extracts 
according to the producer’s protocol on a 96-well plate. 
An equal amount of protein (15 μg/well) was loaded in 
duplicates for each sample. Provided non-specific binding 
control, competitor dsDNA control and positive control 
were used to monitor appropriate assay function. The 96-
well plate was incubated 2 h at room temperature, washed 
with kit wash buffer, and primary antibody was added. 
After 1 h, the plate was washed, incubated with secondary 
antibody, washed again and incubated with kit developing 
solution for 30 min. Finally, kit stop solution was applied 
and absorbance at 450 nm was measured immediately. The 
result is presented as NF-κB (p65) DNA-binding activity 
relative to IL-1β pre-stimulation (100 %).
Enzyme-linked immunosorbent assay (ELISA)
To detect secreted proteins, IVD cells in passage 1-3 
were seeded on 6-well plates (3 x 105 cells/well) (n = 5) 
or in alginate beads (n = 9), serum starved for 2 h and 
then exposed to 10 ng/mL IL-1β for 2 h before treatment 
with 10 μM EGCG. Cell culture medium was collected 
after 18 h and the level of IL-6 protein expression was 
analysed by ELISA according to the producer’s protocol 
(Human IL-6 ELISA set, 555220 with Reagent set B, 
550534, BD Biosciences, San Jose, CA, USA). Briefly, 
96-well plates were coated by kit capture antibody at 
4 °C overnight, washed and blocked in kit assay diluent. 
After washing, samples with controls and standards were 
incubated on the plates for 2 h at room temperature. Then 
plates were washed, kit detection antibody, streptavidin-
horseradish peroxidase (HRP) and substrate solution were 
applied according to the producer’s protocol. Absorbance 
was measured within 30 min at 450 nm with 570 nm 
correction after the addition of a kit stop solution. Results 
are presented as protein expression relative to IL-1β pre-
stimulation (100 %).
In vivo study on pain behaviour
All animal experiments were carried out under the control 
of the Animal Care and Use Committee in accordance with 
local guidelines for animal experiments and government 
law concerning the protection and control of animals. 
Female Sprague-Dawley rats (n = 60, 200-250 g) 
(Japan SLC, Shizuoka, Japan) were used in this study. 
A combination of 0.3 mL medetomidine hydrochloride 
(1.0 mg/mL), 0.8 mL midazolam (5.0 mg/mL), and 1.0 mL 
butophanol tartrate (5.0 mg/mL) was prepared as an 
anaesthetic. Animals were anaesthetised by intraperitoneal 
injection of 0.1 mL/100 g body weight of the mixed 
anaesthetic. Animals were placed in a prone position and 
the surgical intervention was performed with a stereo 
operating microscope and microsurgical instruments. An 
incision was made to the spinal midline, then fascia and 
multifidus muscle were resected, and the left L5 nerve root 
and dorsal root ganglion (DRG) were exposed to L5-L6 
facetectomy on the left side, with great care taken to avoid 
trauma to the tissue. In the NP application group (NP group, 
n = 48), autologous NP was harvested from the tail and 
applied to the DRG (Kobayashi et al., 2011; Otoshi et al., 
2010; Sekiguchi et al., 2011). In the sham-operated group 
(Sham group, n = 12), the left L5 nerve root and DRG were 
exposed to L5-L6 facetectomy, but no other procedures 
were performed. Animals from the NP application group 
were divided into four groups (n = 12 in each): NP + EGCG 
10 µM (0.1 mL of 10 µM EGCG), NP + EGCG 100 µM 
(0.1 mL of 100 µM EGCG), NP + water (0.1 mL of water 
as a vehicle), and NP (non-treatment) group. Animals in the 
treatment groups were injected with 0.1 mL of the designed 
treatment solution into the underlayer of epineurium, just 
distal to the NP, before closing the incisions (Kobayashi et 
al., 2011; Wuertz et al., 2011). Sensitivity to non-noxious 
mechanical stimuli was tested using the von Frey Filament 
test. Baseline testing was performed before the start of 
the experiment to accommodate animals with normal 
responses. Hind paw withdrawal response to von Frey hair 
(North Coast Medical, Morgan Hill, CA, USA) stimulation 
of the plantar surface of the footpads was determined at 
2, 7, 14, 21 and 28 d after surgery. Individual rats were 
placed in an acrylic cage with a mesh floor and allowed to 
acclimate for 15 min or until cage exploration and major 
grooming activities ceased. The lateral plantar surface of 
the operated hind paw, innervated by the L5 nerve, was 
stimulated with nine von Frey filaments (1.02, 1.4, 2.0, 4.1, 
6.1, 8.0, 10.6, 15.4 and 26.0 g) threaded under the mesh 
floor. The gram ratings for von Frey hairs were based on 
the ratings supplied by the manufacturer. The filaments 
were sequentially applied to the paw surface just until 
the filament bent and was held for 3 s. The response was 
considered positive if the rat lifted the foot in combination 
with either licking or shaking of the foot as an escape 
response (Kobayashi et al., 2011; Wuertz et al., 2011).
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Statistical analysis
Statistical significance between IL-1β and IL-1β+EGCG 
groups (Figs. 1, 2) as well as between IL-1β and IL-
1β+SB groups (Fig. 3) was analysed using Student’s t-test. 
Asterisks represent a significance level of p ˂  0.05. For the 
animal study, behavioural data between the groups over 
the experimental period (28 d) was statistically evaluated 
by ANOVA with Bonferroni post-hoc testing to correct for 
multiple comparisons. Asterisks represent a significance 
level of p ˂ 0.01.
Results
EGCG causes a significant decrease in the 
expression of inflammatory mediators and matrix 
metalloproteinases in IVD cells cultured in vitro
The effect of EGCG on the expression of inflammatory 
mediators and matrix metalloproteinases was determined 
in adherent 2D cell culture and in 3D alginate beads on 
the mRNA level after 18 h. A significant inhibition of 
mRNA expression of interleukins (IL-6, IL-8), matrix 
metalloproteinases (MMP1, MMP3, MMP13), toll-like 
receptor 2 (TLR2), nerve growth factor (NGF), inducible 
nitric oxide synthase (iNOS) and cyclooxygenase 2 
(COX-2) was detected upon EGCG treatment in both, 
2D and 3D (Fig. 1a, 1b). The exact values for each gene, 
including p-values, are listed in Table 3. To confirm these 
observations on the protein level, IL-6 was chosen to be 
measured in cell culture media by ELISA, due to its strong 
regulation on the mRNA level and pathological relevance. 
EGCG treatment significantly decreased IL-6 secretion 
into the medium, compared to the IL-1β pre-stimulated 
cells both in 2D (31.26 %, p = 0.0007) and 3D (64.45 %, 
p = 0.0012) (Fig. 1c). Displaying the data relative to the 
IL-1β pre-stimulation (set as 100 %) minimises the inter-
donor variation and shows clearly the effect of the studied 
compound on the acute inflammatory response.
EGCG inhibits IL-1β-induced IRAK-1 degradation 
and partially blocks NF-κB, p38 and JNK activity
IRAK-1 was reported to be important for the transduction 
of inflammatory signals (IL-1β, LPS), which cause its 
phosphorylation and degradation, hence enabling the 
activation of stress-related signalling molecules NF-κB, 
p38 and JNK (Janssens and Beyaert, 2003). IL-1β pre-
Fig. 1. EGCG exhibits anti-inflammatory and anti-catabolic effects in 2D and 3D IVD cell culture. Cells were 
pre-stimulated with IL-1β for 2 h before treatment with EGCG and compared to cells treated with IL-1β or EGCG 
separately. After 18 h, EGCG significantly reduced mRNA expression of IL-6, IL-8, MMP1, MMP3, MMP13, TLR2, 
NGF, iNOS and COX-2, both in 2D adherent cell culture (a) and in 3D alginate beads (b). IL-6 protein secretion in 
cell culture media was also significantly decreased (c). Data are presented as mRNA or protein expression relative 
to IL-1β pre-stimulation. Asterisks indicate statistical significance (p ˂ 0.05, Student’s t-test).
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Fig. 2. EGCG inhibits IRAK-1 and NF-κB/p38 /JNK signalling in IVD cells. Cells were pre-stimulated with IL-1β for 2 h 
before EGCG was added. After 15 min, cells were lysed and western blotting was performed. IRAK-1 degradation (a) and 
p38 and JNK phosphorylation (b) were inhibited upon EGCG treatment of IL-1β-stimulated cells. Combination of IL-1β 
with EGCG partially blocks NF-κB (p65) translocation to the nucleus (c) and NF-κB (p65) DNA-binding activity (d) after 
1 h. Asterisk indicates statistical significance (p ˂ 0.05, Student’s t-test).
Fig. 3. EGCG supresses p38 MAPK-dependent MMP1, MMP13, iNOS and COX-2 expression in IL-1β pre-stimulated 
IVD cells. Cells were pre-stimulated with IL-1β for 2 h before treatments with EGCG or SB203580 (SB). Control cells 
were either untreated or treated with IL-1β, EGCG or SB separately. After 18 h, EGCG and SB203580 both reduced 
mRNA expression of MMP1, MMP13, iNOS and COX-2 (a). Data are presented as mRNA expression relative to IL-1β 
pre-stimulation. Asterisks indicate statistical significance (p ˂ 0.05, Student’s t-test). The function of p38 MAPK inhibitor 
SB203580 was confirmed by western blotting (b). The addition of EGCG or SB to IL-1β-stimulated cells inhibits p38-
dependent COX-2 protein expression (c).
379 www.ecmjournal.org
O Krupkova et al.                                                                                        EGCG in the treatment of IVD degeneration
stimulated IVD cells were treated with EGCG and the level 
of IRAK-1, together with the activity of its downstream 
effectors p38 and JNK, were determined by Western 
blotting. IRAK-1 was degraded in the cells stimulated with 
IL-1β, but the level of IRAK-1 degradation was reduced in 
cells treated with IL-1β + EGCG (Fig. 2a). Phosphorylation 
of p38 and JNK was also decreased in IL-1β + EGCG-
treated cells, compared to IL-1β-stimulated cells, i.e. 
EGCG reduced p38 and JNK activity (Fig. 2b). The effect 
of EGCG on the activity of the transcription factor NF-
κB was studied by immunofluorescence, visualising the 
translocation of NF-κB subunit p65 (RelA) to the nucleus 
and by NF-κB (p65) Transcription Factor Assay. The 
effect of EGCG + IL-1β studied by immunocytochemistry 
prevented p65 translocation in approximately 50 % of 
cells. Cells without primary antibody, untreated cells and 
cells treated with IL-1β were used as controls. As nuclear 
NF- κB was still detectable in the EGCG + IL-1β-treated 
cells (Fig. 2c), a Transcription Factor Assay was performed 
to quantify the nuclear localisation of NF-κB in EGCG + 
IL-1β-treated cells through measurement of DNA binding 
activity. Results of the Transcription Factor Assay showed 
50.83 % (p = 0.0327) decrease in NF-κB DNA-binding 
activity upon EGCG treatment (Fig. 2d). Results are 
presented as NF-κB DNA binding activity relative to IL-
1β-stimulated cells (100 %). A suggested mechanism of 
EGCG action in IVD cells is shown in Fig. 5.
EGCG inhibits p38 MAPK-dependent expression of 
COX-2, iNOS, MMP1 and MMP13
As shown in Fig. 2, EGCG modulates the IRAK-1 and 
p38 signalling pathway in IVD cells. In order to reveal 
which inflammation-related molecules are regulated by 
p38 MAPK on the gene expression level, a small molecule 
inhibitor of p38 MAPK, SB203580 (SB), was used. IL-1β 
pre-stimulated cells were treated with either EGCG or SB 
and mRNA expression was measured after 18 h. Both, 
EGCG and SB treatment significantly inhibits COX-2 (SB: 
26.79 %, p = 0.0151), iNOS (SB: 19.39 %, p = 0.0042), 
MMP1 (SB: 44.54 %, p = 0.0494) and MMP13 (SB: 
6.66 %, p = 0.0042) expression compared to IL-1β pre-
stimulated cells (100 %) (p ˂ 0.05) (Fig. 3a). The ability 
of SB to inhibit p38 activity was confirmed by Western 
blotting (Fig. 3b). The regulation of COX-2 expression 
by EGCG and SB was proved also at the protein level by 
Western blotting (Fig. 3c). The expression of other studied 
genes (IL-6, IL-8, MMP3, TLR2, NGF) is only partially 
p38 dependent or p38 independent (data not shown).
Fig. 4. EGCG inhibits pain behaviour in vivo. Pain sensitivity was measured by the von Frey filament test 
for 28 d. When NP tissue was placed on the DRG without therapeutic treatment (NP group and NP + water 
group), the mechanical withdrawal thresholds were significantly decreased. EGCG treatment (NP + EGCG 
10 µM, NP + EGCG 100 µM) prevented the decrease in the mechanical withdrawal threshold observed in 
the NP group and NP + water group and restored the threshold level to that observed in the sham group.
Gene
2D 3D
Expression, p-Value Expression, p-Value
IL-6 22.72 % p ˂ 0.0001 32.79 % p = 0.0002
IL-8 4.99 % p ˂ 0.0001 25.69 % p = 0.0002
MMP1 30.40 % p ˂ 0.0001 41.40 % p = 0.0013
MMP3 19.73 % p ˂ 0.0001 32.55 % p = 0.0020
MMP13 28.93 % p ˂ 0.0001 54.08 % p = 0.0096
TLR2 10.43 % p ˂ 0.0001 3.25 % p = 0.0001
NGF 10.67 % p = 0.0002 46.79 % p = 0.0003
iNOS 5.91 % p ˂ 0.0001 45.44 % p = 0.0096
COX-2 20.68 % p ˂ 0.0001 39.62 % p = 0.0067
Table 3. Percentage of mRNA expression in samples 
treated with IL-1β + EGCG, relative to IL-1β pre-
stimulation, shown in Fig. 1.
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Fig. 5. Schematic of suggested mechanism of EGCG action in IVD cells. Upon IL-1β stimulation IRAK-1 is 
phosphorylated and degraded, which enables the formation of multiprotein complex (TRAF6/TAB1/TAKs) and 
activation of key stress-related effectors NF-κB, p38 and JNK which are further involved in the activation of 
inflammation, matrix breakdown and pain (A). EGCG blocks IRAK-1 degradation, formation of multiprotein 
complex and hence subsequent activation of NF-κB, p38 and JNK (B). TRAF6, TNF receptor-associated factor 6; 
TAK, TGF-beta activated kinase 1; TABs, TGF-beta activated kinase 1 binding proteins.
Baseline day 2 day 7 day 14 day 21
sham 26±0 23.5±8.0 22.8±7.2 15.6±9.5 16.6±9.2
NP 26±0 10.2±6.3 9.5±6.3 5.7±4.7 9.1±6.2
NP + water 26±0 10.9±5.9 7±1.8 7.8±3.9 9.9±6.2
NP + EGCG 10 µM 26±0 15±7.3 11.5±7.5 15.4±8.5 17.8±8.9
NP + EGCG 100 µM 26±0 16.9±8.7 11.9±7.0 17.5±10.6 19.6±8.4
Table 4. The mean hind paw withdrawal thresholds for each group and 
time point.
sham NP NP + water NP + EGCG 10 NP + EGCG 100
sham x p = 0.0001 p < 0.0001 non-significant non-significant
NP p = 0.0001 x non-significant p = 0.0098 p = 0.0004
NP + water p < 0.0001 non-significant x p = 0.0026 p < 0.0001
NP + EGCG 10 µM non-significant p = 0.0098 p = 0.0026 x non-significant
NP + EGCG 100 µM non-significant p = 0.0004 p < 0.0001 non-significant x
Table 5. Statistical analysis of von Frey filament test between the groups.
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EGCG inhibits pain behaviour in vivo
Animal behaviour in response to mechanical stimulation by 
von Frey filaments was compared between the NP + EGCG 
treatment groups (NP + EGCG 10 µM or NP + EGCG 
100 µM), the NP group (NP + no treatment), the water 
group (NP + water) and the sham group (only facetectomy). 
Furthermore, the NP + EGCG treatment groups were 
compared between each other. In the NP groups without 
EGCG treatment, the mechanical withdrawal thresholds 
were significantly decreased for 28 d compared with the 
sham group, indicating that pain was evoked by application 
of NP tissue to the DRG. Over the experimental period, 
mechanical withdrawal thresholds upon EGCG treatment 
were significantly higher than in the NP group and NP + 
water group, and reached levels measured in the sham 
group. The mean hind paw withdrawal thresholds for each 
group at each time point are listed in Table 4. The exact 
p-values for each comparison are listed in Table 5. Results 
indicate that EGCG treatment reduced pain perception and 
this effect was independent of the applied concentration 
of EGCG (NP + EGCG 10 µM vs. NP + EGCG 100 µM 
= n.s.). Decrease in the mechanical withdrawal threshold 
observed in the sham group arises from facetectomy-
related distress (Fig. 4).
Discussion
The herein presented study clearly demonstrates the anti-
inflammatory and anti-catabolic properties of EGCG in 
human IVD cells in vitro, hence highlights its potential for 
the treatment of IVD-related back pain. The development 
of back pain involves both nociceptive and neuropathic 
pathophysiological mechanisms (Forster et al., 2013; 
Morlion, 2011), with IVD degeneration being one of the 
major underlying causes. IVD degeneration is induced 
by phenotypic changes in the NP cells, leading to tissue 
degradation (Vo et al., 2013), as well as to promotion of 
neoinnervation of the disc and hence the transmission of 
pain in vivo (Alimasi et al., 2013; Richardson et al., 2012). 
The evidence that IVD degeneration and low back pain 
are correlated with increased levels of pro-inflammatory 
cytokines is increasing (Wuertz et al., 2012). Inflammatory 
processes are regulated, for example, by toll-like receptors 
(TLRs), which are primarily expressed on the immune 
cells as a first line of host defence, but have also been 
detected in the other cell types, including IVD cells 
(Ellman et al., 2012; Yoon et al., 2008). Recently, our 
group confirmed basal expression of TLRs in IVD cells 
and showed that expression of TLR2, 4 and 6 is increased 
during IVD degeneration (Klawitter et al., 2014), thus 
further underlying the clinical relevance of inhibiting 
IVD inflammation. In this study, we demonstrated 
that 10 μM EGCG can significantly inhibit the mRNA 
expression of inflammatory and pain-related mediators 
IL-6, IL-8, TLR2, NGF, iNOS and COX-2 and matrix 
metalloproteinases MMP1, MMP3 and MMP13 in 2D 
and 3D IL-1β-stimulated IVD cell culture models. All 
of these markers have been described to be of relevance 
during IVD degeneration and inflammation and hence 
pain development (Gabr et al., 2011; Wuertz and Haglund, 
2013). Although all cells used in this study were isolated 
from degenerated discs, the difference in the expression 
of studied inflammation-related genes between the 
untreated control group and the EGCG-treated group is 
not significant, because basal expression of these genes 
decreases when cells are transferred to in vitro conditions 
(data not shown).
 While this is the first IVD-related study, protective 
effects of EGCG and green tea extract have been reported 
in inflammatory arthritis (Shen et al., 2012), where EGCG 
was shown to block IL-1β-induced expression of IL-6, 
IL-7, IL-8, IL-1β, TNF-α (Akhtar and Haqqi, 2011), 
MMP1 and MMP13 (Ahmed et al., 2004), iNOS (Singh 
et al., 2002) and COX-2 (Heinecke et al., 2010), and these 
effects were linked mostly to NF-κB and JNK signalling 
pathways (Ahmed et al., 2002; Akhtar and Haqqi, 2011; 
Rasheed et al., 2009; Singh et al., 2002; Singh et al., 2003). 
In order to determine the underlying mechanisms in the 
IVD, potential pathways were identified from the literature 
(Ahmed et al., 2002; Akhtar and Haqqi, 2011; Rasheed et 
al., 2009; Singh et al., 2002; Singh et al., 2003) and the 
effects of EGCG on IRAK-1 degradation as well as NF-
kB and MAPK activity in IVD cells were analysed. We 
propose that EGCG acts as an IL-1 receptor antagonist in 
IL-1β-stimulated IVD cells. Our suggested mechanism 
of action, which is illustrated in Fig. 5, is through the 
inhibition of IRAK-1 degradation. As IL-1 receptors 
do not possess intrinsic kinase activity, they rely on the 
recruitment and activation of intrinsic kinases (IRAKs) 
(Janssens and Beyaert, 2003). Upon phosphorylation, 
IRAK-1 is ubiquitinated and degraded, which initiates 
the formation of a cytosolic multi-protein complex. The 
IRAK-1-activated protein complex is involved in the 
phosphorylation of the inhibitor of κB kinase (IKK) as well 
as of MAPK kinases 3/4/6, leading to the activation of NF-
κB and JNK/p38 MAPKs, respectively (Burns et al., 2003; 
Janssens and Beyaert, 2003). In this study, we demonstrate 
inhibition of IRAK-1 degradation in IVD cells, similar to 
IL-1β-stimulated OA chondrocytes (Akhtar and Haqqi, 
2011). As a result, activity of NF-κB was decreased in 
IL-1β-stimulated EGCG-treated IVD cells. This effect 
was observed after 1 h, since NF-κB is a protein complex 
that functions as a “rapid-acting” transcription factor and 
as such regulates the transcription of more than 150 genes 
related to stress responses, including MMPs (Elliott et al., 
2002; Liacini et al., 2003; Mengshol et al., 2000; Wuertz 
et al., 2012).
 The inhibition of IRAK-1 degradation is accompanied 
by a decrease in the activity of its downstream effectors 
p38 and JNK. p38 kinase is a MAPK family member 
that is activated in various stress conditions, such as UV 
irradiation, hypoxia, oxidative stress and inflammation, 
and regulates the expression of many stress-related genes, 
leading either to restoration of homeostasis or to alteration 
of cellular functions and apoptosis. Recently it was 
published that blockage of p38 MAPK activity in rabbit 
(Studer et al., 2008) and human (Studer et al., 2007) NP 
cells reduces IL-1β-induced NO and prostaglandin E-2 
accumulation (Kim et al., 2012; Studer et al., 2008) and 
partially restores proteoglycan synthesis (Studer et al., 
2008). Using the small-molecule inhibitor SB203580, we 
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confirmed that not only iNOS and COX-2 but also MMP1 
and MMP13 are p38 MAPK target genes in human IVD 
cells (similar to bovine IVD cells (Seguin et al., 2006)), 
hence indicating that the p38 pathway may play an 
essential role in ECM degradation and nociception in the 
disc. Importantly, the concomitant regulation of MMP1 
and MMP13 suggests that EGCG may slow down MMP-
induced collagen loss in all stages of IVD degeneration, 
as MMP1 has been shown to be significantly increased in 
severely degenerated NPs whereas MMP13 is increased 
in earlier stages of NP degeneration (Le Maitre et al., 
2004; Vo et al., 2013). The expression of other studied 
genes (IL-6, IL-8, MMP3, TLR2 and NGF) is regulated 
differently in IVD cells, although p38 may co-operate too. 
In the context of nociception, the observed decrease in 
the prostaglandin H synthase COX-2 can be specifically 
relevant as it catalyses the initial step in the conversion of 
arachidonic acid to prostaglandins, which have a variety 
of physiological effects including sensitisation of spinal 
neurons to pain (Studer et al., 2008). Similarly, NOS plays 
an important role in the processing of pain (Meller and 
Gebhart, 1993), so that the reduction of iNOS expression 
by EGCG should be highlighted. Interestingly, it was 
recently reported that intrathecal administration of EGCG 
could produce an antiallodynic effect against spinal nerve 
ligation-induced neuropathic pain, mediated by blockade 
of neuronal NOS protein expression and inhibition of nitric 
oxide (NO) (Choi et al., 2012). As described above, our 
in vitro results suggest that EGCG-driven p38-mediated 
inhibition of COX-2 and iNOS expression may be helpful 
for nociceptive as well as neuropathic pain reduction. In 
order to monitor changes in pain behaviour upon EGCG 
treatment in vivo, we used an animal model in which NP-
mediated pain is simulated by the application of NP tissue 
to the DRG, thus representing typical radiculopathic pain 
(Kato et al., 2008; Sasaki et al., 2007; Tachihara et al., 
2008). EGCG treatment was able to prevent the threshold 
reduction and thus the pain-related behaviour. The full 
recovery to the sham threshold level was observed on day 
14 in both EGCG treatment groups. Our results correspond 
to recent findings using the rat model of neuropathic pain 
(sciatic nerve constriction) where intrathecal injection 
of EGCG markedly improved pain behaviour in rats and 
decreased the expression of TLR4, NF-κB, high-mobility 
group protein B1 (HMGB1), tumour necrosis factor alpha 
(TNF-α) and IL-1β in the spinal cord (Kuang et al., 2012). 
In humans, back pain is however caused by complex 
interactions of biological, psychological and social factors 
and can be considered as a syndrome with both nociceptive 
and neuropathic components (mixed pain) (Forster et 
al., 2013). Nociceptive nerves are a major transmitter of 
discogenic back pain (Freemont, 2009), therefore alteration 
of nerve ingrowth into the disc by EGCG-mediated 
inhibition of neurotrophins can modulate the development 
of acute and chronic nociceptive pain. On the other 
hand, discogenic radiculopathy occurs when functional, 
vascular and morphological changes of the nerve root are 
activated, e.g. by disc-related inflammation, which leads to 
intraradicular fibrosis and nerve fibre atrophy (Freemont, 
2009). From this point of view and according to our in vivo 
results, EGCG-mediated inhibition of the inflammatory 
response of NP tissue may be beneficial also against the 
development of disc-related radiculopathy. Based on 
these results, we hypothesise that EGCG may reduce pain 
behaviour in vivo by inhibiting the expression of cytokines 
and pain-related inflammatory mediators, similar to the 
mechanism observed in our in vitro cell culture study.
 This study however has certain limitations; firstly, the 
mechanism of EGCG action is not entirely clear. During 
disc degeneration, the regulation and function of the IL-1-
mediated pathway is altered: IL-1α and IL-1β isoforms as 
well as IL-1 receptor are synthesised in larger quantities 
compared to healthy tissue, whereas the expression of 
IL-1 receptor antagonist is unchanged (Le Maitre et al., 
2007b). This imbalance activates the IL-1 pathway in NP 
tissue, which leads to the induction of the expression of 
MMPs, ADAMTs, as well as to enhanced angiogenesis 
and neurogenesis (Freemont, 2009). Although our study 
does not address the exact mechanism of how EGCG 
influences the IL-mediated pathway, it provides evidence 
that EGCG can act as an IL-1 pathway antagonist, therefore 
can possibly help to restore tissue homeostasis in vivo. 
The second limitation is that NP cells were isolated from 
donors with different medical conditions due to the limited 
number of available biopsies. In addition, exact separation 
of NP and AF tissue (which was performed in the surgical 
as well as the laboratory setting) can be challenging in 
degenerated material so that certain impurities are possible. 
Nevertheless, all donors respond similarly. Finally, the 
effect of EGCG at the tissue level (matrix degradation) 
was not analysed in this study.
 Considering the anti-inflammatory, anti-catabolic and 
analgesic properties of EGCG presented in this study, we 
suggest that EGCG could in the future supplement or even 
substitute drugs which are used currently for the treatment 
of low back pain and disc degeneration. However, the 
best mode of application is still a matter of debate. While 
oral application has been considered for diseases such as 
obesity or diabetes, large in vitro/in vivo discrepancy was 
observed (Mereles and Hunstein, 2011) due to the low 
bioavailability of EGCG, with an elimination half-life in 
plasma of around 3.5 h (Lee et al., 2002). For the treatment 
of back pain, oral application of EGCG is certainly not a 
promising approach because the inflammatory processes 
within the IVD need to be targeted directly. Therefore, local 
application (e.g. intradiscal or epidural injection) will be 
required, which could be done in conjunction with other 
surgical or regenerative interventions or independently, i.e. 
as an early, non-invasive treatment. However, it is likely 
that the effects of non-modified (free) EGCG will be less 
pronounced in vivo compared to in vitro because of its 
low stability, which can be further influenced by extrinsic 
conditions such as type of storage and intrinsic factors such 
as Ca2+ and Mg2+ ions or antioxidant concentration (Mereles 
and Hunstein, 2011). Encapsulation of EGCG in polymeric 
carriers represents a promising strategy to increase its 
bioavailability and release period. In fact, different types 
of polymeric carriers administered orally or intravenously 
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were demonstrated to significantly increase the stability and 
efficiency of EGCG in cancer therapy (Wang et al., 2012; 
Wang et al., 2013), showing their potential to be used also 
inside the IVD. However, the disc-specific environment 
(high level of proteoglycan, lower pH in degenerated disc, 
low number of cells) should be taken into account when 
choosing a carrier and delivery method for EGCG. The 
efficacy of these respective EGCG slow-release systems 
will have to be determined in vitro using cell or organ 
culture studies (by detecting inflammation) as well as in 
appropriate in vivo models (by detecting pain sensation). 
Despite the remaining challenges, EGCG offers several 
potential clinical advantages: it is globally available, it 
is inexpensive to isolate, it was reported to be safe and 
well tolerated, and clinically active concentrations can be 
reached by its oral administration or by its modification 
(Bode and Dong, 2009; Singh et al., 2011).
Conclusion
In this study, we examined the effects of the bioactive 
polyphenol from green tea, epigallocatechin 3-gallate, 
on IVD cells cultured in 2D and 3D in vitro and on IVD-
related radiculopathic pain in vivo. We have described 
its anti-inflammatory and anti-catabolic effects and the 
benefit of EGCG in the reduction of both nociceptive and 
neuropathic disc-related pain. We identified IRAK-1 and 
NF-κB/p38/JNK signalling pathways to be modulated by 
EGCG and we provide evidence that this contributes to the 
observed effects. Although precise mechanisms of EGCG 
action and its direct targets in IVD cells still need to be 
elucidated, we showed promising therapeutic potential of 
EGCG in the treatment of disc-related inflammation and 
back pain in degenerative disc disease.
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Discussion with Reviewers
Reviewer I: If the effects of the EGCG are short lived and it 
has a half-life in plasma of only 3.5 h, how can we explain 
that effect in vivo was not seen until week 2?
Authors: The half-life of EGCG has been reported to 
be 3.5 h in human plasma. In rodent animal models, the 
activity of intracellular and extracellular enzymes can be 
different, e.g. due to the efficiency of peroxidases that 
decrease the activity of EGCG by oxidation (Patry et al., 
2003). In our animal experiment, the improvement in the 
hind paw withdrawal threshold is not observed until the day 
7 after the application of EGCG. One explanation for the 
delayed effect in rats can be a difference in the occurrence 
and activity of EGCG-degrading enzymes between rat and 
human tissue. The effect of EGCG can decrease via its 
oxidation by myeloperoxidase and eosinophil peroxidase, 
which are secreted by activated leukocytes involved in 
the clearance of displaced NP tissue. A second reason 
for delayed anti-inflammatory response in this animal 
model can be the anti-catabolic activity of EGCG itself, 
which can initially inhibit the MMPs from leukocytes 
that are involved in the clearance of displaced NP tissue. 
Furthermore, EGCG can mediate receptor/enzyme activity 
by inhibiting inflammation-related signalling pathways, 
which, according to our in vitro results, activate the cellular 
response at the level of gene expression within 24 h. 
Therefore, the observed delayed analgesic effect in vivo can 
occur partially due to a general inhibition of inflammation 
in the displaced NP tissue, rather than due to the quick 
blockage of pain development (nerve root reaction).
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